Orbimed Capital, Shareholder: Enliven Therapeutics ELVN Planned sale · Filed 06/22

Trade details

Type: Planned sale notice
Stock: Enliven Therapeutics ELVN
Person: Orbimed CapitalShareholder
Planned sale date: 26/06/22
Filed: 26/06/22

More to sell after $461.1K in 3 months

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 05/23~07/22

Orbimed Capital's recent trades

Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$80.3K
1,747 sh
$80.3K
Filed 06/22
Traded 06/22
Orbimed CapitalShareholder
Planned saleEnliven Therapeutics
Planned sale
Enliven Therapeutics
ELVN
$433.9K
10,243 sh
$433.9K
Filed 06/15
Traded 06/15
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$7.5M
1,689,189 sh
$7.5M
Filed 04/23
Traded 04/21
Orbimed CapitalDirector
BuyPrelude Therapeutics
Buy
Prelude Therapeutics
PRLD
$5M
1,126,126 sh
$5M
Filed 04/23
Traded 04/21
Orbimed CapitalDirector, Shareholder
Planned saleCompass Therapeutics
Planned sale
Compass Therapeutics
CMPX
$5.7M
3,571,428 sh
$5.7M
Filed 25/04/09
Traded 25/04/09